Article Details
Retrieved on: 2024-06-25 16:00:03
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Ethris's successful Phase I trial results for its mRNA antiviral drug ETH47, aimed at treating respiratory diseases like uncontrolled asthma. The connection to 'business intelligence' lies in leveraging trial data and funding insights to advance drug development and market strategies in healthcare.
Article found on: www.pharmaceutical-technology.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here